ACUT
Price
$1.97
Change
-$0.02 (-1.01%)
Updated
Sep 5 closing price
Capitalization
31.66M
VRNA
Price
$106.31
Change
+$0.07 (+0.07%)
Updated
Sep 5 closing price
Capitalization
9.2B
66 days until earnings call
Interact to see
Advertisement

ACUT vs VRNA

Header iconACUT vs VRNA Comparison
Open Charts ACUT vs VRNABanner chart's image
Accustem Sciences
Price$1.97
Change-$0.02 (-1.01%)
Volume$1.78K
Capitalization31.66M
Verona Pharma
Price$106.31
Change+$0.07 (+0.07%)
Volume$2.48M
Capitalization9.2B
ACUT vs VRNA Comparison Chart in %
Loading...
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACUT vs. VRNA commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACUT is a Hold and VRNA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ACUT: $1.97 vs. VRNA: $106.31)
Brand notoriety: ACUT and VRNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACUT: 24% vs. VRNA: 58%
Market capitalization -- ACUT: $31.66M vs. VRNA: $9.2B
ACUT [@Biotechnology] is valued at $31.66M. VRNA’s [@Biotechnology] market capitalization is $9.2B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACUT’s FA Score shows that 1 FA rating(s) are green whileVRNA’s FA Score has 1 green FA rating(s).

  • ACUT’s FA Score: 1 green, 4 red.
  • VRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ACUT and VRNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACUT’s TA Score shows that 3 TA indicator(s) are bullish while VRNA’s TA Score has 3 bullish TA indicator(s).

  • ACUT’s TA Score: 3 bullish, 5 bearish.
  • VRNA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, VRNA is a better buy in the short-term than ACUT.

Price Growth

ACUT (@Biotechnology) experienced а +3.14% price change this week, while VRNA (@Biotechnology) price change was +0.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

VRNA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRNA($9.2B) has a higher market cap than ACUT($31.7M). ACUT YTD gains are higher at: 339.732 vs. VRNA (128.919). ACUT has higher annual earnings (EBITDA): -1.54M vs. VRNA (-34.62M). VRNA has more cash in the bank: 438M vs. ACUT (31.3K). ACUT has less debt than VRNA: ACUT (66.4K) vs VRNA (244M). VRNA has higher revenues than ACUT: VRNA (222M) vs ACUT (0).
ACUTVRNAACUT / VRNA
Capitalization31.7M9.2B0%
EBITDA-1.54M-34.62M4%
Gain YTD339.732128.919264%
P/E RatioN/AN/A-
Revenue0222M-
Total Cash31.3K438M0%
Total Debt66.4K244M0%
FUNDAMENTALS RATINGS
VRNA: Fundamental Ratings
VRNA
OUTLOOK RATING
1..100
24
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
PROFIT vs RISK RATING
1..100
2
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACUTVRNA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 27 days ago
80%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 23 days ago
80%
Bearish Trend 27 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 2 days ago
73%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ACUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PCY21.270.22
+1.05%
Invesco Emerging Markets Sov Debt ETF
HYXU55.250.34
+0.63%
iShares International High Yield Bd ETF
IPAY59.37-0.21
-0.35%
Amplify Digital Payments ETF
EEV11.55-0.29
-2.42%
ProShares UltraShort MSCI Emerging Mkts
COIW37.96-1.17
-2.99%
Roundhill COIN WeeklyPay ETF

ACUT and

Correlation & Price change

A.I.dvisor tells us that ACUT and LGVN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACUT and LGVN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACUT
1D Price
Change %
ACUT100%
-0.88%
LGVN - ACUT
30%
Poorly correlated
+5.84%
OKYO - ACUT
28%
Poorly correlated
+0.44%
APVO - ACUT
20%
Poorly correlated
-1.23%
VRNA - ACUT
20%
Poorly correlated
+0.07%
CLRPF - ACUT
9%
Poorly correlated
N/A
More

VRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with RYTM. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then RYTM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
+0.07%
RYTM - VRNA
46%
Loosely correlated
-2.34%
ZYME - VRNA
42%
Loosely correlated
+6.89%
IRON - VRNA
42%
Loosely correlated
+0.95%
CRNX - VRNA
37%
Loosely correlated
+3.97%
OCUL - VRNA
37%
Loosely correlated
+7.09%
More